am -
pm ET

Frequently Asked Questions (FAQs)

What is Alnylam Assist™?

Alnylam Assist™ includes Case Managers, Patient Education Liaisons, and Field Reimbursement Directors who provide support to patients prescribed Alnylam therapies. This support includes: verification of insurance benefits, coverage and reimbursement education, financial assistance support for eligible patients, and disease and product education. Each member of our team is assigned to specific geographic regions to work with patients, their caregivers, healthcare providers, and insurance companies to support patients throughout treatment on OXLUMO® (lumasiran). See how Alnylam Assist can support you throughout treatment ›

How do I get started in the Alnylam Assist™ program?

In order to enroll in the program, you must be prescribed OXLUMO and fill out the Start Form with your doctor. Once the form is completed and you've signed it, your doctor can submit the form online or print it out and fax it to Alnylam Assist™. Find out more about getting started ›

What support services does Alnylam Assist™ provide?

Alnylam Assist™ focuses on 3 key areas of support services for patients and their families: insurance benefit verification, financial assistance options for eligible patients, and disease and product education. Find out more about the support services offered›

Who are Case Managers?

Case Managers are experienced in helping individuals get started on treatment and providing ongoing product support. They will tailor their method of communication to what works best for you.

An Alnylam Case Manager can help you understand your insurance coverage and options for financial support based on eligibility, as well as provide you with educational resources. Learn how you can work together with an Alnylam Case Manager ›

Who are Patient Education Liaisons (PELs)?

PELs have backgrounds in nursing and are experienced in educating individuals and their families about matters related to primary hyperoxaluria type 1 (PH1). PELs can help you in a variety of ways, including providing disease and product education, connecting you to additional resources, and answering questions about treatment with OXLUMO. PELs are employees of Alnylam Pharmaceuticals. They are not acting as healthcare providers and are not part of your healthcare team. Learn about the PEL team and how to get connected ›

What additional resources are available?

In addition to the personalized services that are part of Alnylam Assist™, there are also educational and support resources for patients and their families. These include downloadable materials about PH1 and treatment with OXLUMO, as well as links to advocacy groups that connect patients to the PH1 community. Find out what’s available to support you and your family ›

What if I'm a caregiver?

Alnylam Assist is here to support you by helping your loved one access OXLUMO® and providing you education about PH1. We can also connect you to independent organizations that can offer additional resources ›

How can I contact Alnylam Assist?

A Case Manager from Alnylam Assist™ is available from 8am - 6pm, Monday - Friday at 1-833-256-2748.

Alnylam Assist® get started icon

See How to Get Started

Once you and your doctor decide to begin treatment with OXLUMO, we'll work with your healthcare team to start the process.

How to Get Started

Alnylam Assist® Case Manager Kevin

Call Kevin


Monday - Friday, 8am - 6pm

Alylam Separator Triangles


The most common side effect of OXLUMO is injection site reaction (redness, swelling, pain, bruising, itching, and discoloration at the site of injection). These are not all the possible side effects of OXLUMO. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

OXLUMO has not been studied in pregnant or breastfeeding women. Talk to your doctor about the risk of taking OXLUMO if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed.


OXLUMO is a prescription medicine for the treatment of primary hyperoxaluria type 1 (PH1) to lower oxalate in urine and blood in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.